The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
β2‐adrenoceptor agonists: current and future direction
Open accessAbstract
Despite the passionate debate over the use of β 2‐adrenoceptor agonists in the treatment of airway disorders, these agents are still central in the symptomatic management of asthma and COPD. A variety of β 2‐adrenoceptor agonists with long half‐lives, also called ultra long‐acting β 2‐adrenoceptor agonists (ultra‐LABAs; indacaterol, olodaterol, vilanterol, carmoterol, LAS100977 and PF‐610355) are currently under development with the hopes of achieving once‐daily dosing. It is likely that the once‐daily dosing of a bronchodilator would be a significant convenience and probably a compliance‐enhancing advantage, leading to improved overall clinical outcomes. As combination therapy with an inhaled corticosteroid (ICS) and a LABA is important for treating patients suffering from asthma, and a combination with an inhaled long‐acting antimuscarinic agent (LAMA) is important for treating COPD patients whose conditions are not sufficiently controlled by monotherapy with a β 2‐adrenoceptor agonist, some novel once‐daily combinations of LABAs and ICSs or LAMAs are under development. LINKED ARTICLES This article is part of a themed issue on Respiratory Pharmacology. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.163.issue‐1
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-456so · Cited by 4,925
Global strategy for asthma management and prevention: GINA executive summary
Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S. E., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00138707 · Cited by 3,203
(2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.09.029 · Cited by 2,181
O'Donnell, D. E., Voduc, N., Fitzpatrick, M., & Webb, K. A. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00072703 · Cited by 365
Cited by
Pharmacology and Therapeutics of Bronchodilators
Cazzola, M., Page, C. P., Calzetta, L., & Matera, M. G. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004580 · Cited by 467
Self-citationImpact of GPCR Structures on Drug Discovery
Congreve, M., de Graaf, C., Swain, N. A., & Tate, C. G. (2020) · Cell · doi:10.1016/j.cell.2020.03.003 · Cited by 375
Drug Delivery to the lungs: Challenges and Opportunities
Newman, S. P. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0037 · Cited by 328
Prevention of Acute Exacerbations of COPD
Criner, G. J., Bourbeau, J., Diekemper, R. L., Ouellette, D. R., Goodridge, D., Hernandez, P., Curren, K., Balter, M. S., Bhutani, M., Camp, P. G., et al. (2015) · Chest · doi:10.1378/chest.14-1676 · Cited by 288
β 2 -Agonist Therapy in Lung Disease
Cazzola, M., Page, C. P., Rogliani, P., & Matera, M. G. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201209-1739pp · Cited by 262
Self-citation
Metadata
- Authors
- Cazzola, M., Calzetta, L., & Matera, M. G.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-04-06
- Volume
- 163
- Issue
- 1
- Pages
- 4-17
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1997210895
- Cited by
- 158
- References
- 5
- FWCI
- 14.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: β2‐adrenoceptor agonists: current and future direction. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01216.x
- The paper
- Cazzola, M., Calzetta, L., & Matera, M. G. (2011). β2‐adrenoceptor agonists: current and future direction. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01216.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.